Links
- ORCID
- ORCID
- ORCID
- Crossref | PDF
- [dx.doi.org] | PDF
- [boris.unibe.ch]
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [boris.unibe.ch] | PDF
- [opus.bibliothek.uni-wuerzburg.de] | PDF
- [europepmc.org] | PDF
- [epub.ub.uni-muenchen.de] | PDF
Tools
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Journal article published in 2014 by
Ulrike Proetel,
,
Nadine Pletsch,
Hofmann Wk,
Michael Lauseker,
Martin C. Müller,
Müller Mc,
Benjamin Hanfstein,
Stefan W. Krause 
,
Lida Kalmanti,
Krause Sw,
Annette Schreiber,
Markus Pfirrman,
Gabriela M. Baerlocher,
Dominik Heim
and other authors.
,
Lida Kalmanti,
Krause Sw,
Annette Schreiber,
Markus Pfirrman,
Gabriela M. Baerlocher,
Dominik Heim
and other authors.
Abstract
Other ; The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid leukemia in chronic phase. Patients randomized to imatinib 400 mg/day (IM400) or imatinib 800 mg/day (IM800) and stratified according to age (≥65 years vs.